This is a phase 3 open label, multi-center, randomized, active-controlled non-inferiority trial that compares the safety and effectiveness of a 6-week regimen of daily rifapentine against the current standard of 12-16 weeks of rifamycin-based treatment for latent TB infection (LTBI).
The George Washington University is seeking volunteers for a LTBI clinical trial who are:
- 18 years and older and living in the DC metro area
- Require treatment of LTBI and are at increased risk of progression to tuberculosis
More information regarding the study can be found at clinicaltrials.gov.